人纤维蛋白原的临床应用研究进展  

Research progress of clinical application of human fibrinogen

作　　者：刘鸽 陈强 褚忠君 吴恒趋[3] LIU Ge;CHEN Qiang;CHU Zhongjun(School of Life Sciences,East China Normal University,Shanghai 200221,China;Shanghai RAAS Blood Products Co Ltd)

机构地区：[1]华东师范大学生命科学学院,上海200221 [2]上海莱士血液制品股份有限公司 [3]上海交通大学医学院附属仁济医院

出　　处：《中国输血杂志》2021年第8期935-938,共4页Chinese Journal of Blood Transfusion

摘　　要：在各种原因导致的出血事件中,患者往往由于凝血因子的大量消耗或丧失导致凝血功能障碍进而危及生命。近年来,使用人纤维蛋白原预防或治疗出血的医学证据不断出现,为临床治疗出血事件提供了更多的选择。本文对人纤维蛋白原稳定性、药代动力学和安全性,及在产科、心脏外科、创伤性大出血等临床应用的最新进展进行了归纳总结,并对人纤维蛋白原的临床应用提出了新的合理化建议。In bleeding events caused by various reasons,coagulation dysfunction due to massive consumption or loss of coagulation factors is often life-threatening.In recent years,medical evidence of using human fibrinogen concentrate to prevent or treat bleeding has emerged,providing more options for clinical treatment of bleeding.In this paper,the stability,pharmacokinetics and safety of human fibrinogen,as well as the latest advances in its clinical application in obstetrics,cardiac surgery and traumatic massive hemorrhage were summarized,and new reasonable suggestions for clinical application of human fibrinogen were also put forward.

关 键 词：人纤维蛋白原 临床前研究 临床应用 

分 类 号：R457.1[医药卫生—治疗学]